Cargando…

Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling

This study aimed to determine the expression of progranulin (PGRN) in hepatocellular carcinoma (HCC) cells in response to interleukin 6 (IL-6), a non-cellular component of the tumor microenvironment, and the molecular mechanism of PGRN oncogenic activity in hepatocarcinogenesis. Levels of IL-6 and P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Feng, Zhang, Wen, Yang, Fusheng, Feng, Tingting, Zhou, Meng, Yu, Yuan, Yu, Xiuping, Zhao, Weiming, Yi, Fan, Tang, Wei, Lu, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754634/ https://www.ncbi.nlm.nih.gov/pubmed/26879559 http://dx.doi.org/10.1038/srep21260

Ejemplares similares

Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway
por: Feng, Tingting, et al.
Publicado: (2016)

mTOR up-regulation of SNRPA1 contributes to hepatocellular carcinoma development
por: Feng, Jing, et al.
Publicado: (2020)

PSME4 Activates mTOR Signaling and Promotes the Malignant Progression of Hepatocellular Carcinoma
por: Ge, Sijia, et al.
Publicado: (2022)

Progranulin Facilitates Conversion and Function of Regulatory T Cells under Inflammatory Conditions
por: Wei, Fanhua, et al.
Publicado: (2014)

The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells
por: Cheng, Jin-Shiung, et al.
Publicado: (2019)

Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents
por: Feng, Ying-Qi, et al.
Publicado: (2020)

Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma
por: Feng, Ying-Qi, et al.
Publicado: (2020)

mTOR Regulation of Metabolism in Hematologic Malignancies
por: Mirabilii, Simone, et al.
Publicado: (2020)

Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells
por: Zhen, Mao-Chuan, et al.
Publicado: (2016)

USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling
por: Huang, Wen-ya, et al.
Publicado: (2022)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma
por: Chen, Xinhuang, et al.
Publicado: (2017)

Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
por: Ferrín, Gustavo, et al.
Publicado: (2020)

Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway
por: Ge, Yiqin, et al.
Publicado: (2016)

FUS contributes to mTOR-dependent inhibition of translation
por: Sévigny, Myriam, et al.
Publicado: (2021)

Progranulin deficiency leads to severe inflammation, lung injury and cell death in a mouse model of endotoxic shock
por: Yu, Yuan, et al.
Publicado: (2016)

eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway
por: Sun, Liping, et al.
Publicado: (2021)

GTSE1 Facilitates the Malignant Phenotype of Lung Cancer Cells via Activating AKT/mTOR Signaling
por: Zhang, Fan, et al.
Publicado: (2021)

mTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and Treatment
por: Wang, Zhuo, et al.
Publicado: (2014)

Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
por: Dittmer, Dirk P, et al.
Publicado: (2012)

mTOR signaling contributes to motor skill learning in mice
por: Bergeron, Yan, et al.
Publicado: (2014)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2019)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

S100 calcium-binding protein A10 contributes to malignant traits in osteosarcoma cells by regulating glycolytic metabolism via the AKT/mTOR pathway
por: Ling, Feng, et al.
Publicado: (2022)

MLXIPL promotes the migration, invasion, and glycolysis of hepatocellular carcinoma cells by phosphorylation of mTOR
por: Chang, Xiaowei, et al.
Publicado: (2023)

The activation of mTOR signalling modulates DNA methylation by enhancing DNMT1 translation in hepatocellular carcinoma
por: Chen, Mengke, et al.
Publicado: (2023)

The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
por: Todeschini, Letizia, et al.
Publicado: (2023)

FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway
por: Meng, Wen, et al.
Publicado: (2020)

The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
por: Geissler, Edward K
Publicado: (2013)

Mechanical Stimulation Induces mTOR Signaling via an ERK-Independent Mechanism: Implications for a Direct Activation of mTOR by Phosphatidic Acid
por: You, Jae Sung, et al.
Publicado: (2012)

Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022)

Plasma levels of progranulin and interleukin-6 in frontotemporal lobar degeneration
por: Gibbons, Linda, et al.
Publicado: (2015)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

TFEC contributes to cardiac hypertrophy by inhibiting AMPK/mTOR signaling
por: Zhao, Ting, et al.
Publicado: (2021)

Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion
por: Shanware, Naval P., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gbk5tfiveki2rv9uu35sd3gegj